Cargando…

Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells

Phenoxodiol is a novel isoflav-3-ene, currently undergoing clinical trials, that has a broad in vitro activity against a number of human cancer cell lines. Phenoxodiol alone inhibited DU145 and PC3 in a dose- and time-dependent manner with IC(50) values of 8±1 and 38±9 μM, respectively. The combinat...

Descripción completa

Detalles Bibliográficos
Autores principales:	McPherson, R A C, Galettis, P T, de Souza, P L
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653737/ https://www.ncbi.nlm.nih.gov/pubmed/19209173 http://dx.doi.org/10.1038/sj.bjc.6604920

Ejemplares similares

Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects in vitro and in vivo
por: Georgaki, Sylvianna, et al.
Publicado: (2009)

The effects of phenoxodiol on the cell cycle of prostate cancer cell lines
por: Mahoney, Simon, et al.
Publicado: (2014)

Nicotine increases the resistance of lung cancer cells to cisplatin through enhancing Bcl-2 stability
por: Nishioka, T, et al.
Publicado: (2014)

Enhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts
por: Shiirevnyamba, A, et al.
Publicado: (2011)

BCAS2 promotes prostate cancer cells proliferation by enhancing AR mRNA transcription and protein stability
por: Kuo, P-C, et al.
Publicado: (2015)

Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells
por: Johansson, D, et al.
Publicado: (2010)

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer
por: Wilson, C, et al.
Publicado: (2008)

Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes
por: Teng, P-N, et al.
Publicado: (2014)

Involvement of Cyr61 in growth, migration, and metastasis of prostate cancer cells
por: Sun, Z-J, et al.
Publicado: (2008)

MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells
por: Ponnusamy, M P, et al.
Publicado: (2008)

Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells
por: Terakawa, T, et al.
Publicado: (2009)

The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro
por: O'Brien, P M, et al.
Publicado: (2008)

Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients
por: McCall, P, et al.
Publicado: (2008)

Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer
por: Mukherjee, R, et al.
Publicado: (2011)

Is PTEN loss associated with clinical outcome measures in human prostate cancer?
por: McCall, P, et al.
Publicado: (2008)

Phenoxodiol protects against Cisplatin induced neurite toxicity in a PC-12 cell model
por: Klein, Reuben, et al.
Publicado: (2007)

Secreted Frizzled-related protein-1 is a negative regulator of androgen receptor activity in prostate cancer
por: Kawano, Y, et al.
Publicado: (2009)

Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer
por: Tam, L, et al.
Publicado: (2007)

Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer
por: Attard, G, et al.
Publicado: (2008)

Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer
por: Kamoshida, S, et al.
Publicado: (2007)

TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer
por: Knight, J F, et al.
Publicado: (2008)

Effects of platelet-activating factor and its differential regulation by androgens and steroid hormones in prostate cancers
por: Xu, B, et al.
Publicado: (2013)

DKC1 overexpression associated with prostate cancer progression
por: Sieron, P, et al.
Publicado: (2009)

Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo
por: Gassler, N, et al.
Publicado: (2005)

Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues
por: Riddick, A C P, et al.
Publicado: (2005)

Activation of nuclear factor-κB in human prostate carcinogenesis and association to biochemical relapse
por: Domingo-Domenech, J, et al.
Publicado: (2005)

The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells
por: Henderson, D J P, et al.
Publicado: (2014)

Phorbol ester stimulates ethanolamine release from the metastatic basal prostate cancer cell line PC3 but not from prostate epithelial cell lines LNCaP and P4E6
por: Schmitt, J, et al.
Publicado: (2014)

Ligand-independent activation of EphA2 by arachidonic acid induces metastasis-like behaviour in prostate cancer cells
por: Tawadros, T, et al.
Publicado: (2012)

Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers
por: Went, P, et al.
Publicado: (2006)

Inhibition of constitutive and cxc-chemokine-induced NF-κB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells
por: Seaton, A, et al.
Publicado: (2009)

Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells
por: Dixon, K M, et al.
Publicado: (2013)

Study of matrix metalloproteinases and their inhibitors in prostate cancer
por: Escaff, S, et al.
Publicado: (2010)

Impact of differential cyclin D1 expression and localisation in prostate cancer
por: Comstock, C E S, et al.
Publicado: (2007)

Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer
por: Sørensen, K D, et al.
Publicado: (2013)

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models
por: Oliva, P, et al.
Publicado: (2012)

Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients
por: Willder, J M, et al.
Publicado: (2013)

Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial
por: Huang, Jiaqi, et al.
Publicado: (2016)

ERK5 signalling in prostate cancer promotes an invasive phenotype
por: Ramsay, A K, et al.
Publicado: (2011)

FTIR-based spectroscopic analysis in the identification of clinically aggressive prostate cancer
por: Baker, M J, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_1h3qmv38cu3tmjg6athao7627i